| Entry |
|
|---|
| Name |
Lumiliximab (USAN/INN);
Gomiliximab (USAN) |
|---|
| Formula |
C6850H10656N1824O2106S50
|
|---|
| Exact mass |
153764.8843
|
|---|
| Mol weight |
153860.21
|
|---|
| Efficacy |
Antiallergic, Antiasthmatic, Antineoplastic, Anti-CD23 antibody |
|---|
| Type |
Monoclonal antibody |
|---|
| Comment |
Treatment of allergic asthma, allergic rhinitis, and chronic lymphocytic leukemia
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Brite |
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD23
D06463 Lumiliximab (USAN/INN)
|
|---|
| Other DBs |
|
|---|
